Significance of serum IgA in patients with acute hepatitis E virus infection

Table 1 Prevalence of anti-HEV IgM and anti-HEV IgA in different groups of subjects

Group	n	Age (mean ± SD)	Anti-HEV IgA, n (%)	Anti-HE IgM, n (%)	Anti-HEV IgG, n (%)	HEV RNA, n (%)
Hepatitis A	62	33.1 ± 11.2	2 (3.2)	1 (1.6)	1 (1.6)	0
Hepatitis B	100	36.3 ± 12.2	1 (1)	0	10 (10)	0
Hepatitis C	56	45.6 ± 15.3	1 (1.8)	1 (1.8)	1 (1.8)	0
Autoimmune hepatitis	52	40.5 ± 10.1	0	2 (3.8)	3 (5.8)	0
Rheumatoid arthritis	40	56.4 ± 9.4	0	2 (5)	1 (2.5)	0
Blood donors	100	36.8 ± 18.5	2 (2)	1 (1)	8 (8)	1 (1)
Hepatitis E	100	52.6 ± 14.8	100 (100)	100 (100)	98 (98)	60 (60)

Table 2 Serum anti-HEV IgA, anti-HEV IgM, HEV RNA, ALT and TBil

T/mo	HEV RNA n (%)	Anti-HEV-IgA n (%)	Anti-HEV -IgM n (%)	Anti-HEV -IgG n (%)	ALT (mean ± SD) nkat/L	TBil (mean± SD μmol/L
-0.5	60 (100)	60 (100)	60 (100)	59 (98)	1117 ± 200	86 ± 17
-1	36 (60)	60 (100)	60 (100)	60 (100)	4101 ± 884	506 ± 123
-2	3 (5)	58 (97)a	46 (77)	60 (100)	1850 ± 750	198 ± 68
-3	0	56 (93)b	34 (57)	60 (100)	800 ± 250	84 ± 31
-4	0	38 (3)b	12 (20)	60 (100)	567 ± 183	46 ± 14
-5	0	18 (0)b	2 (3)	60 (100)	467 ± 150	23 ± 8

^aP < 0.05,

^bP< 0.01 compared with anti-HEV IgM positive results.